Document Type : Original Article(s)
Authors
1 Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran
2 School, of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background: In epithelial ovarian cancer (EOC), frequently diagnosed at an advanced stage, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery is a standard approach. Cancer antigen-125 (CA-125) is the cornerstone biomarker for monitoring treatment response, yet the prognostic value of its post-NACT levels and dynamic change relative to survival outcomes remains incompletely defined, particularly regarding optimal cutoffs for risk stratification in real-world clinical practice. This study aimed to investigate whether post-NACT CA-125 levels and their percentage reduction from baseline are independently associated with progression-free survival (PFS) and overall survival (OS) in patients with advanced (FIGO stage III–IV) EOC.
Methods: We performed a retrospective analysis of a synthetic cohort of 100 patients, modeled on real-world data. Pre- and post-NACT CA-125 levels were evaluated using Pearson correlation, Kaplan-Meier survival analysis, and multivariate Cox regression. Patients were stratified by post-treatment CA-125 (<50 vs. ≥50 U/mL) and percentage reduction (≥80% vs. <80%).
Results: Post-NACT CA-125 <50 U/mL (n = 42) was correlated with significantly longer PFS (median: 18.2 vs. 9.5 months; (hazard ratio) HR = 0.52, P = 0.002) and OS (48.3 vs. 32.1 months; HR = 0.61, P = 0.008). Similarly, ≥80% reduction (n = 58) was associated with improved PFS (16.7 vs. 10.4 months, P = 0.003) and OS (45.1 vs. 36.8 months, P = 0.015).
Conclusion: Post-NACT CA-125 levels and their dynamic reduction are robust prognostic biomarkers for survival in advanced EOC, supporting their integration into therapeutic follow-up for enhanced risk stratification. Prospective validation in real-world cohorts is warranted.
Highlights
Zahra Shiravani (google scholar)
Keywords
- Epithelial ovarian cancer
- Peritoneal cancer index
- Overall survival
- Progression-free survival
- CA-125 antigen
Main Subjects
Please cite this article as: Najib F, Shiravani Z, Khoshdel M, Aghdaki M. Post-neoadjuvant chemotherapy cancer antigen-125 levels and their association with progression-free and overall survival in advanced‑stage epithelial ovarian cancer. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.106949.2277.
- Clancy E. ACS Report Shows Prostate Cancer on the Rise, Cervical Cancer on the Decline. [Internet] Renal & Urology News. 2023.[cited 2023, February 23]. Available at: https://www.renalandurologynews.com/news/acs-report-prostate-cancer-on-rise-cervical-cancer-on-decline/
- Zheng P, Zheng P, Chen G. Conditional survival of advanced epithelial ovarian cancer: A real-world data retrospective cohort study from the SEER database. Front Med (Lausanne). 2021;8:756401. doi: 10.3389/fmed.2021.756401. PMID: 34888325; PMCID: PMC8650058.
- Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403-15. doi: 10.1056/NEJMoa1909707. PMID: 31562800; PMCID: PMC6941439.
- Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;29(4):728-60. doi: 10.1136/ijgc-2019-000308. PMID: 31048403.
- Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. PMID: 26002111.
- Osborn G, Stavraka C, Adams R, Sayasneh A, Ghosh S, Montes A, et al. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol. 2022;209(1):4-21. doi: 10.1093/cei/uxab020. PMID: 35020853; PMCID: PMC9307234.
- Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17(8):1234-8. doi: 10.1093/annonc/mdl120. PMID: 16766592.
- Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34(32):3854-63. doi: 10.1200/JCO.2016.68.1239. PMID: 27601552; PMCID: PMC5477982.
- Tanner EJ, Garg K, Leitao MM Jr, Soslow RA, Hensley ML. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol. 2012;127(1):27-31. doi: 10.1016/j.ygyno.2012.06.030. PMID: 22750260.
- Merlo S, Besic N, Drmota E, Kovacevic N. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer. Radiol Oncol. 2021;55(3):341-6. doi: 10.2478/raon-2021-0013. PMID: 33675192; PMCID: PMC8366730.
- Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014;24(4):889-901. doi: 10.1007/s00330-013-3083-8. PMID: 24322510.
- Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361(2):170-7. doi: 10.1056/NEJMcp0901926. PMID: 19587342.
- Kordowitzki P, Lange B, Elias KM, Haigis MC, Mechsner S, Braicu IE, et al. Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J Clin. 2025;75(5):436-60. doi: 10.3322/caac.70008. PMID: 40252048; PMCID: PMC12432820.
- Chan JK, Tian C, Kesterson JP, Richardson MT, Lin K, Tewari KS, et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. Gynecol Oncol. 2022;167(3):429-35. doi: 10.1016/j.ygyno.2022.09.028. PMID: 36244828.
- Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005;23(25):5938-42. doi: 10.1200/JCO.2005.08.151. PMID: 16087942.
- Fallon EA, Awiwi MO, Bhutiani N, Helmink B, Scally CP, Mansfield P, et al. Peritoneal cancer index correlates with radiographic assessment of colorectal carcinomatosis. Ann Surg Oncol. 2025;32:2923-31. doi: 10.1245/s10434-024-16737-0. PMID: 39730964; PMCID: PMC12244292.
- Llueca A, Climent MT, Escrig J, Carrasco P, Serra A. Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer. Sci Rep. 2021;11:8111. doi: 10.1038/s41598-021-86928-2. PMID: 33854085; PMCID: PMC8047030.
- Ngo TV, Dao LT, Tran AD, Le CT, Nguyen HX, Phung HT. Prognostic value of CT-PCI and CA-125 changes following neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A retrospective study from Vietnam. Gynecol Oncol Rep. 2025;61:101927. doi: 10.1016/j.gore.2025.101927. PMID: 41169956; PMCID: PMC12570090.
- Perrone AM, Coada CA, Ravegnini G, De Leo A, Damiano G, De Crescenzo E, et al. Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer. 2023;33(8):1270-8. doi: 10.1136/ijgc-2022-004249. PMID: 37429642; PMCID: PMC10423511.
)